🏢 官网IRXENECodex · 实盘不做把握 9/10
北京时间·🕒 发布 07-31 04:01:27(美东 07-30 16:01)·⟳ 抓取 07-31 04:05:25 +3m58s·⚡ 决策 08-01 03:36:48 +23h31m·88.0 天前
Xenon宣布将于8月6日披露二季度业绩并举行电话会
本次只是例行财报发布时间和电话会预告，没有披露业绩、指引、临床进展或融资等新增基本面信息。
📄 原文XENE↗ 原文
Xenon to Report Q2 2026 Financial Results on August 6, 2026
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscien…
不做 Xenon Pharmaceuticals（XENE.US）
例行财报发布时间预告，没有业绩数字、指引变化、临床结果或其它方向性新增信息，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 low · price-in 风险 high ↗
关键理由
- 本次只是例行财报发布时间和电话会预告，没有披露业绩、指引、临床进展或融资等新增基本面信息。
主要风险
- 真正可能产生交易信号的是8月6日盘后披露的业绩和业务更新，而不是本次日程公告。
原文全文
展开原文 · 2,061 字
VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026.
Company Presentation Details:
Date:
Thursday, August 6, 2026
Time:
4:30pm ET (1:30pm PT)
Webcast:
Pre-register here
Dial-In:
(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:
5286122
A live webcast of the company presentation will be available on the
Investors
section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K
V
7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K
V
7 and Na
V
1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit
xenon-pharma.com
and follow us on
LinkedIn
and
X
.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com
Company Presentation Details:
Date:
Thursday, August 6, 2026
Time:
4:30pm ET (1:30pm PT)
Webcast:
Pre-register here
Dial-In:
(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:
5286122
A live webcast of the company presentation will be available on the
Investors
section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent K
V
7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K
V
7 and Na
V
1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit
xenon-pharma.com
and follow us on
and
X
.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。